BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 27030211)

  • 1. Zyxin-Siah2-Lats2 axis mediates cooperation between Hippo and TGF-β signalling pathways.
    Ma B; Cheng H; Gao R; Mu C; Chen L; Wu S; Chen Q; Zhu Y
    Nat Commun; 2016 Mar; 7():11123. PubMed ID: 27030211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase.
    Ma B; Chen Y; Chen L; Cheng H; Mu C; Li J; Gao R; Zhou C; Cao L; Liu J; Zhu Y; Chen Q; Wu S
    Nat Cell Biol; 2015 Jan; 17(1):95-103. PubMed ID: 25438054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway.
    Zhu C; Ji X; Zhang H; Zhou Q; Cao X; Tang M; Si Y; Yan H; Li L; Liang T; Feng XH; Zhao B
    J Biol Chem; 2018 Jan; 293(4):1178-1191. PubMed ID: 29183995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2.
    Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS
    Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes the development of castration resistance.
    Guo Y; Cui J; Ji Z; Cheng C; Zhang K; Zhang C; Chu M; Zhao Q; Yu Z; Zhang Y; Fang YX; Gao WQ; Zhu HH
    Oncogene; 2017 Nov; 36(45):6336-6347. PubMed ID: 28745315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation.
    Pefani DE; Pankova D; Abraham AG; Grawenda AM; Vlahov N; Scrace S; O' Neill E
    Mol Cell; 2016 Jul; 63(1):156-66. PubMed ID: 27292796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The characterisation of LATS2 kinase regulation in Hippo-YAP signalling.
    Hoa L; Kulaberoglu Y; Gundogdu R; Cook D; Mavis M; Gomez M; Gomez V; Hergovich A
    Cell Signal; 2016 May; 28(5):488-497. PubMed ID: 26898830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.
    Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K
    Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WBP2 promotes gastric cancer cell migration via novel targeting of LATS2 kinase in the Hippo tumor suppressor pathway.
    Hum M; Tan HJ; Yang Y; Srivastava S; Teh M; Lim YP
    FASEB J; 2021 Feb; 35(2):e21290. PubMed ID: 33475198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lats2 modulates adipocyte proliferation and differentiation via hippo signaling.
    An Y; Kang Q; Zhao Y; Hu X; Li N
    PLoS One; 2013; 8(8):e72042. PubMed ID: 23977200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIBRA regulates Hippo signaling activity via interactions with large tumor suppressor kinases.
    Xiao L; Chen Y; Ji M; Dong J
    J Biol Chem; 2011 Mar; 286(10):7788-7796. PubMed ID: 21233212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers.
    Li W; Wang L; Katoh H; Liu R; Zheng P; Liu Y
    Cancer Res; 2011 Mar; 71(6):2162-71. PubMed ID: 21278236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1/BARD1-dependent ubiquitination of NF2 regulates Hippo-YAP1 signaling.
    Verma S; Yeddula N; Soda Y; Zhu Q; Pao G; Moresco J; Diedrich JK; Hong A; Plouffe S; Moroishi T; Guan KL; Verma IM
    Proc Natl Acad Sci U S A; 2019 Apr; 116(15):7363-7370. PubMed ID: 30918126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LATS2 Inhibits Malignant Behaviors of Glioma Cells via Inactivating YAP.
    Shi Y; Geng D; Zhang Y; Zhao M; Wang Y; Jiang Y; Yu R; Zhou X
    J Mol Neurosci; 2019 May; 68(1):38-48. PubMed ID: 30771084
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Kim E; Kang JG; Kang MJ; Park JH; Kim YJ; Kweon TH; Lee HW; Jho EH; Lee YH; Kim SI; Yi EC; Park HW; Yang WH; Cho JW
    Proc Natl Acad Sci U S A; 2020 Jun; 117(25):14259-14269. PubMed ID: 32513743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor.
    Paramasivam M; Sarkeshik A; Yates JR; Fernandes MJ; McCollum D
    Mol Biol Cell; 2011 Oct; 22(19):3725-33. PubMed ID: 21832154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth control: re-examining Zyxin's role in the hippo pathway.
    Harvey KF
    Curr Biol; 2015 Mar; 25(6):R230-R231. PubMed ID: 25784041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nonreceptor tyrosine kinase c-Src attenuates SCF(β-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
    Shanzer M; Adler J; Ricardo-Lax I; Reuven N; Shaul Y
    Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1678-1683. PubMed ID: 28154141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LATS2 induced by TNF-alpha and inhibited cell proliferation and invasion by phosphorylating YAP in oral squamous cell carcinoma.
    Dong C; Wei KJ; Zhang WB; Sun H; Pan HY; Zhang L
    J Oral Pathol Med; 2015 Jul; 44(6):475-81. PubMed ID: 25782587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.